Calidi Biotherapeutics Statistics
Total Valuation
CLDI has a market cap or net worth of $8.26 million. The enterprise value is $2.40 million.
Important Dates
The next estimated earnings date is Tuesday, August 12, 2025, after market close.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CLDI has 33.59 million shares outstanding. The number of shares has increased by 488.87% in one year.
| Current Share Class | 31.79M |
| Shares Outstanding | 33.59M |
| Shares Change (YoY) | +488.87% |
| Shares Change (QoQ) | +77.16% |
| Owned by Insiders (%) | 3.77% |
| Owned by Institutions (%) | 8.24% |
| Float | 27.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.19 |
| P/TBV Ratio | 1.19 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.12, with a Debt / Equity ratio of 0.64.
| Current Ratio | 2.12 |
| Quick Ratio | 1.96 |
| Debt / Equity | 0.64 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -26.71 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -111.74% |
| Return on Invested Capital (ROIC) | -274.58% |
| Return on Capital Employed (ROCE) | -208.40% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$770,536 |
| Employee Count | 28 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, CLDI has paid $13,000 in taxes.
| Income Tax | 13,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -87.86% in the last 52 weeks. The beta is 0.94, so CLDI's price volatility has been similar to the market average.
| Beta (5Y) | 0.94 |
| 52-Week Price Change | -87.86% |
| 50-Day Moving Average | 0.37 |
| 200-Day Moving Average | 0.98 |
| Relative Strength Index (RSI) | 30.56 |
| Average Volume (20 Days) | 1,649,959 |
Short Selling Information
The latest short interest is 366,602, so 1.09% of the outstanding shares have been sold short.
| Short Interest | 366,602 |
| Short Previous Month | 269,387 |
| Short % of Shares Out | 1.09% |
| Short % of Float | 1.35% |
| Short Ratio (days to cover) | 0.74 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -20.09M |
| Pretax Income | -29.96M |
| Net Income | -21.58M |
| EBITDA | -19.70M |
| EBIT | -20.09M |
| Earnings Per Share (EPS) | -$1.55 |
Full Income StatementBalance Sheet
The company has $10.56 million in cash and $4.71 million in debt, giving a net cash position of $5.86 million or $0.17 per share.
| Cash & Cash Equivalents | 10.56M |
| Total Debt | 4.71M |
| Net Cash | 5.86M |
| Net Cash Per Share | $0.17 |
| Equity (Book Value) | 7.30M |
| Book Value Per Share | 0.21 |
| Working Capital | 6.06M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$22.99 million and capital expenditures -$18,000, giving a free cash flow of -$23.01 million.
| Operating Cash Flow | -22.99M |
| Capital Expenditures | -18,000 |
| Free Cash Flow | -23.01M |
| FCF Per Share | -$0.69 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
